New plant, Plant 4

New plant, Plant 4
Product Description

To fulfill the increasing demand of life-saving solutions for patients' lives all over the world, we decided to drive forward with building our new facility, Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your global presence, becoming your future biomanufacturing hub.

Samsung Biologics Co., Ltd.

  • KR
  • 2018
    On CPhI since
  • 1000 - 4999
    Employees
Contract Service

Samsung Biologics Co., Ltd.

  • KR
  • 2018
    On CPhI since
  • 1000 - 4999
    Employees
Contract Service

More Products from Samsung Biologics Co., Ltd.

  • S-Cellerate™ to BLA

    Product S-Cellerate™ to BLA

    As biologics in development get closer to commercialization, drug developers are expected to implement rigorous process control measures to avoid potential manufacturing inconsistencies. A thorough understanding of process parameters and their potential impact on the product quality attributes and safety profilesis critical for a smooth transition from IND to BLA.
  • S-Cellerate™ to IND

    Product S-Cellerate™ to IND

    Speed to market is becoming increasingly crucial for commercial success. Enhanced timelines, which quickly advance the platform product to proof-of-concept (PoC) and first-in-human (FiH) studies, are already the new norm. Samsung Biologics’ S-Cellerate™ represents the faster path to IND, achieved through careful optimization of processes, resources, and timelines to deliver top-quality biologics in record time.

Samsung Biologics Co., Ltd. resources

Recommended products